Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 2, 1997, Pages 909-919

  Iwatsubo, Takafumi ^a   Suzuki, Hiroshi ^b   Shimada, Noriaki ^c   Chiba, Kan ^d   Ishizaki, Takashi ^e   Green, Carol E ^f   Tyson, Charles A ^f   Yokoi, Tsuyoshi ^g   Kamataki, Tetsuya ^g   Sugiyama, Yuichi ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c DAIICHI PURE CHEMICALS CO LTD   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^f SRI INTERNATIONAL   (United States)

^g HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4,5]DECANE TARTARATE MONOHYDRATE; 2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; ANTIBODY; CYTOCHROME B5; CYTOCHROME P450 ISOENZYME; CYTOCHROME P450 REDUCTASE; KETOCONAZOLE; RECOMBINANT ENZYME; TARTARIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; DEMENTIA; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER BLOOD FLOW; LIVER MICROSOME; MALE; METABOLIC CLEARANCE RATE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; RAT;

AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; MALE; MICROSOMES, LIVER; PARASYMPATHOMIMETICS; RECOMBINANT PROTEINS; SPIRO COMPOUNDS;

EID: 8544229104     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. AKAIKE, H.: Fitting autoregressive models for prediction. Ann. Inst. Stat. Math. 21: 243-247, 1969.
2. BISCHOFF, K. B., DEDRICK, R. L., ZAHARKO, D. S. AND LONGSTRETH, J. A.: Methotrexate pharmacokinetics. J. Pharm. Sci. 60: 1128-1133, 1971.
3. BOXENBAUM, H.: Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm. 8: 165-176, 1980.
4. BOXENBAUM, H.: Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10: 201-227, 1982.
5. DEDRICK, R. L.: Animal scale up. J. Pharmacokinet. Biopharm. 1: 435-461, 1974.
6. DEDRICK, R. L., FORESTER, D. D., CANNON, J. N., EL DAREEN, S. M. AND MELLETT, L. B.: Pharmacokinetics of 1-β-D-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem. Pharmacol. 22: 2405-2417, 1973.
7. GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. AND GHANAYEM, B. I.: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752, 1994.
8. HOUSTON, J. B.: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47: 1469-1479, 1994.
9. IMAOKA, S., ENOMOTO, K., ODA, Y., ASADA, A., FUJIMORI, M., SHIMADA, T., FUJITA, S., GUENGERICH, F. P. AND FUNAE, Y.: Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther. 255: 1385-1391, 1990.
10. IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H. AND SUGIYAMA, Y.: Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 17: 1-38, 1996.
11. IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. AND SUGIYAMA, Y.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73: 147-171, 1997.
12. KAMATAKI, T., MAEDA, K., YAMAZOE, Y., NAGAI, T. AND KATO, R.: Partial purification and characterization of cytochrome P-450 responsible for the occurrence of sex difference in drug metabolism in the rat. Biochem. Biophys. Res. Commun. 103: 1-7, 1981.
13. LIN, J. H., SUGIYAMA, Y., AWAZU, S. AND HANANO, M.: Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokinet. Biopharm. 10: 649-661, 1982.
14. MONTANDON, B., ROBERTS, R. J. AND FISCHER, L. J.: Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man. J. Pharmacokinet. Biopharm. 3: 277-290, 1975.
15. NAGATA, K., GONZALEZ, F. J., YAMAZOE, Y. AND KATO, R.: Purification and characterization of four catalytically active testosterone 6-hydroxylase P-450s from rat liver microsomes: Comparison of a novel form with three structurally and functionally related forms. J. Biochem. 107: 718-725, 1990.
16. RANE, A., WILKINSON, G. R. AND SHAND, D. G.: Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200: 420-424, 1977.
17. RENAUD, J.-P., CULLIN, C., POMPON, D., BEAUNE, P. AND MANSUY, D.: Expression of human liver cytochrome P450IIIA4 in yeast: A functional model for the hepatic enzyme. Eur. J. Biochem. 194: 889-896, 1990.
18. ROBERTS, M. S. AND ROWLAND, M.: A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14: 227-260, 1986a.
19. ROBERTS, M. S. AND ROWLAND, M.: Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. J. Pharm. Pharmacol. 38: 177-181, 1986b.
20. SAWADA, Y., HANANO, M., SUGIYAMA, Y. AND IGA, T.: Prediction of the disposition of β-lactam antibiotics in human from pharmacokinetic parameters in animals. J. Pharmacokinet. Biopharm. 12: 241-261, 1984.
21. SESARDIC, D., BOOBIS, A. R., EDWARDS, R. J. AND DAVIES, D. S.: A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J. Clin. Pharmacol. 26: 363-372, 1988.
22. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. AND GUENGERICH, F. P.: Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-422, 1994.
23. SUGIYAMA, Y., SAWADA, Y., IGA, T. AND HANANO, M.: Xenobiotic metabolism and disposition. In Proceedings of the 2nd International ISSX Meeting, ed. by R. Kato, R. W. Estabrook and M. N. Cayen, pp. 225-235, Taylor & Francis, London, 1988.
24. SUGIYAMA, Y. AND IWATSUBO, T.: Physiological pharmacokineties: Prediction of human drug disposition and pharmacokineties from animal data and from in vitro to in vivo. In Proceeding of the International Symposium on the Role of Drug Metabolism and Pharmacokinetic Research in New Drug Development, pp. 45-63, Doping Control Center, Korea Institute of Science and Technology (KIST), 1994.
25. SUZUKI, T., ISOZAKI, S., ISHIDA, R., SAITOH, Y. AND NAKAGAWA, F.: Drug absorption and metabolism studies by use of portal vein infusion in the rat. II: Influence of dose and infusion rate on the bioavailability of propranolol, Chem. Pharm. Bull. 22: 1639-1645, 1974.
26. THUMMEL, K. E., SHEN, D. D., PODOLL, T., KUNZE, K. L., TRAGER, W. F., HARTWELL, P., RAISYS, V. A., MARSH, C. L., MCVICAR, J. P., BARR, D. M., PERKINS, J. D. AND CARITHEBS JR., R. L.: Use of midazolam as a human cytochrome P4503A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271: 549-556, 1994.
27. WILKINSON, G. R.: Clearance approaches in pharmacology. Pharmacol. Rev. 39: 1-47, 1987.
28. YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T. AND UNO, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharm. Dyn. 4: 879-885, 1981.
29. YASUKOCHI, Y. AND MASTERS, B. S. S.: Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem. 251: 5337-5344, 1976.
30. YOSHIMOTO, K., ECHIZEN, H., CHIBA, K, TANI, M. AND ISHIZAKI, T.: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisoprorylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol. 39: 421-431, 1995.